IDEAYA Biosciences Inc at Citi Virtual Oncology Leadership Summit Transcript
Okay. Welcome, everyone. I'm Yigal Nochomovitz, one of the biotech analysts at Citi. This is our Oncology Summit over the next three days. It's my pleasure to have with me Yujiro Hata, the Co-Founder, CEO, and President of IDEAYA Biosciences.
Welcome, Yujiro. Great to see you. I guess maybe to start with, obviously, a lot of people are familiar with your pipeline, but some maybe a little bit less familiar. So if you want to kick us off with a quick overview of IDEAYA, talk about your synthetic lethality platform, and then we can move into more detailed discussion of some of your programs. Thanks.
Great. Thanks so much again for the kind introduction. And thank you to Citi for the opportunity to participate this year in your Oncology Summit. So IDEAYA was founded over seven years ago with a core focus to build the leading synthetic lethality-focused precision medicine oncology company.
Today, we have three clinical programs. Our most advanced is
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
